Indicaciones terapéuticas y paliativas de la cirugía en los tumores pulmonares y torácicos

  1. Casado, D. 1
  2. Bellido, L. 1
  3. Del Barco, E. 1
  4. Cigarral, B. 1
  5. Escalera, E. 1
  6. Claros, J. 1
  7. Barrios, B. 1
  8. Figuero, L. 1
  9. Olivares, A. 1
  10. López, A. 1
  11. Terán, E. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1414-1417

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.007 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

El tratamiento curativo del cáncer de pulmón es, por excelencia, la cirugía torácica. A todo paciente con un tumor pulmonar resecable se le debe ofrecer la posibilidad de tratarlo mediante cirugía. Es imprescindible una correcta estadificación y un debate multidisciplinar para decidir la resecabilidad de un tumor. En estadios precoces, el tratamiento de elección, en aquellos pacientes candidatos a ello, es la cirugía torácica. Es imprescindible una correcta disección ganglionar para confirmar la resección completa del tumor. En los tumores localmente avanzados, es necesaria la valoración en un comité multidisciplinar para su correcto tratamiento. También la cirugía torácica tiene sus indicaciones paliativas para solventar complicaciones derivadas del tumor principal o de sus metástasis.

Referencias bibliográficas

  • Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vans-teenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1-21.
  • Veluswamy RR, Ezer N, Mhango G, Goodman E, Bonomi M, Neugut AI, et al. Limited resection versus lobectomy for older patients with early-stage lung cancer: Impact of histology. J Clin Oncol [Internet]. 2015 Oct 20 [consultado 27 Sep 2020];33(30):3447-53. Disponible en: https://pub-med.ncbi.nlm.nih.gov/26240229/
  • Koike T, Kitahara A, Sato S, Hashimoto T, Aoki T, Koike T, et al. Lobectomy versus segmentectomy in radiologically pure solid small-sized non-small cell lung cancer presented at the Ninety-fifth Annual Meeting of the American Association for Thoracic Surgery, Seattle, WA, April 25-29, 2015. Ann Thorac Surg [Internet]. 2016 Apr 1;101(4):1354-60. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26794890/
  • Ginsberg RJ, Rubinstein L V. Randomized trial of lobectomy versus limi-ted resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg [Internet]. 1995;60(3):615-23. Disponible en:https://pubmed.ncbi.nlm.nih.gov/7677489/
  • Blasberg JD, Pass HI, Donington JS. Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol. 2010 Oct;5(10):1583-93. Disponible en: https://pub-med.ncbi.nlm.nih.gov/20879185/doi: 10.1097/jto.0b013e3181e77604.
  • Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A Phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJO-G4607L). J Clin Oncol [Internet]. 2009 Nov 22;40(3):271-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/ 19933688/
  • Aisner DL, Akerley W, Bauman JR, Bruno DS, Chang JY, Chirieac LR, et al. Continue NCCN Guidelines Panel Disclosures NCCN Guidelines Version 8.2020 Non-Small Cell Lung Cancer. 2020.
  • Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. CLINICAL GUIDES IN ONCOLOGY SEOM clinical guideli-nes for the treatment of non-small cell lung cancer (2018). 2094;21:3-17. Disponible en: https://doi.org/10.1007/s12094-018-1978-1
  • Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, et al. Postoperative radiation therapy is associated with improved overall survi-val in incompletely resected stage II and III non-small-cell lung cancer. J Clin Oncol [Internet]. 2015 Sep 1 [consultado 27 Sep 2020];33(25):2727-34. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26101240/
  • Huang X, Wang J, Chen Q, Jiang J. Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: A systematic review and meta-analysis. PLoS One [Internet]. 2014 Oct 8;9(10). Disponible en: https://pub-med.ncbi.nlm.nih.gov/25296033/
  • Blackmon SH, Cooke DT, Whyte R, Miller D, Cerfolio R, Farjah F, et al. The society of thoracic surgeons expert consensus statement: A tool kit to assist thoracic surgeons seeking privileging to use new technology and perform advanced procedures in general thoracic surgery. Ann Thorac Surg [Internet]. 2016 Mar 1 101(3):1230-7. Disponible en: https://ucdavis.pure.elsevier.com/en/publications/the-so-ciety-of-thoracic-surgeons-expert-consensus-statement-a-too
  • Romaszko AM, Doboszyn ́ ska A. Multiple primary lung cancer: A literature review. Adv Clin Exp Med. 2018;27(5):725-30. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29790681/
  • Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, et al. Ste-reotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer. Cancer [Internet]. 2013 Sep 15;119(18):3402-10. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23798353/
  • Griffioen GHMJ, Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol [Internet]. 2013 Jun;107(3):403-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23746675/
  • Pignon JP, Tribodet H, Scagliotti G V., Douillard JY, Shepherd FA, Ste-phens RJ, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol [Internet]. 2008;26(21):3552-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18506026/
  • Tsitsias T, Boulemden A, Ang K, Nakas A, Waller DA. The n2 paradox: Similar outcomes of pre- and postoperatively identified single-zone n2a positive non-small-cell lung cancer. Eur J Cardio-thoracic Surg [Internet]. 2014 ;45(5):882-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24080282/
  • Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006157.Disponible en: http://doi.wiley.com/10.1002/14651858.CD006157.pub2
  • van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus ra-diotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst [Internet]. 2007 Mar 21;99(6):442-50. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17374834/
  • Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised contro-lled trial. Lancet [Internet]. 2009 Aug 7;374(9687):379-86. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19632716/
  • Kimura M, Tojo T, Naito H, Nagata Y, Kawai N, Taniguchi S. Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination. Interact Cardiovasc Thorac Surg [Internet]. 2010 Apr;10(4):568-71. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20093263/
  • Wolf AS, Flores RM. Extrapleural pneumonectomy for pleural malignan-cies. Thorac Surg Clin. 2014;24(4):471-5 Disponible en: https://pubmed.ncbi.nlm.nih.gov/25441141/
  • Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004;(1):CD002916. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14973997/
  • Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclero-sis for malignant pleural effusion. Chest [Internet]. 2005;127(3):909-15. Disponible en:https://pubmed.ncbi.nlm.nih.gov/15764775/
  • Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. JAMA - J Am Med Assoc [Internet]. 2012 Jun 6;307(22):2383-9. Disponible en: https://jamanetwork.com/
  • Pilling JE, Dusmet ME, Ladas G, Goldstraw P. Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol [Internet]. 2010;5(10):1544-50. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20802350/
  • Van Breussegem A, Hendriks JM, Lauwers P, Van Schil PE. Salvage sur-gery after high-dose radiotherapy. J Thorac Dis. 2017;9Suppl3:S193-S200. Disponible en: /pmc/articles/PMC5392543/ ?report=abstract
  • Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer [Internet]. 2014 Sep 1;15(5):346-55. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24894943/
  • Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physi-cians evidence-based clinical practice guidelines. Chest [Internet]. 2013 May;143Suppl5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23649447/
  • Tönnies M, Pfannschmidt J, Bauer TT, Kollmeier J, Tönnies S, Kaiser D. Metastasectomy for synchronous solitary non-small cell lung cancer metastases. Ann Thorac Surg [Internet]. 2014;98(1):249-56. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24820385/
  • Dómine M, Moran T, Isla D, Martí JL, Sullivan I, Provencio M, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol [Internet]. 2020 Feb 1; 22(2):245-55. Disponible en: https://pub-med.ncbi.nlm.nih.gov/32040815/
  • Ettinger DS, Wood DE, Chair V, Aggarwal C, Aisner DL, Akerley W, et al. NCCN Guidelines Panel Disclosures NCCN Guidelines Version 1.2020 Malignant Pleural Mesothelioma. 2019.
  • Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26Suppl5:v31-9.
  • Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo JC, et al. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020;147:83-90.
  • Ettinger DS, Wood DE, Chair V, Aggarwal C, Aisner DL, Akerley W, et al. NCCN Guidelines Version 1.2020 Thymomas and Thymic Carcinomas. 2019.
  • Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(July):v40-55.
  • Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg [Internet]. 2011 Jul;128(1):305-10. Disponible en: /pmc/articles/PMC3124652/?report=abstrac
Fuente de los datos: Dialnet